However, treatments like bevacizumab, a humanized monoclonal antibody targeting VEGF, and small molecule inhibitors like sorafenib and sunitinib, which target VEGFR, have shown limited efficacy in cancers such as HCC. The gene discussed is KDR; the disease is cancer.